Effect of add-on valproate on craving in methamphetamine depended patients: A randomized trial

Kheirabadi, Gholam Reza; Ghavami, Masoud; Maracy, Mohammad Reza; Salehi, Mehrdad; Sharbafchi, Mohammad Reza

Effect of add-on valproate on craving in methamphetamine depended patients: A randomized trial

Authors

¹ Behavioral Sciences Research Center, Department of Psychiatry, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

² Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Methamphetamine dependence lead to the compulsive use, loss of control, and social and occupational dysfunctions. This study aimed to compare the effect of valproate in reducing the craving in methamphetamine dependents.
Materials and Methods: This is a randomized, double-blind, controlled clinical trial on 40 men of 18–40 years old referred to Noor Hospital during December 2012–September 2013 in Isfahan, Iran. The subjects participated in matrix program and randomly were divided into two groups of valproate and placebo. A 4-months program of intervention with valproate or placebo was arranged for each group. The rate of craving to methamphetamine and positive methamphetamine urine tests were evaluated in both groups every 2 weeks using cocaine craving questionnaire-brief (CCQ-Brief) and urine test. After the 4 months (active treatment with valproate and placebo), the drug was tapered and discontinued within 10 days, and patients were introduced to self-help groups and monitored regularly on a weekly basis over another 3 months. Collected data were analyzed with SPSS 20 using analysis of covariance repeated measure, Chi-square, and t-test.
Results: CCQ score of the intervention group was significantly less than the placebo group (P < 0.001), except on weeks 1, 3, and 28. The ratio of a positive urine test for methamphetamine in the intervention group was significantly lower than the control group in all screenings except weeks 3 and 28.
Conclusion: Adding valproate to matrix program in the treatment of methamphetamine dependence showed significant effect on the reduction of the craving to methamphetamine.

Keywords

References

1.	McCann UD, Ricaurte GA. Amphetamine (or Amphetamine-like) – Related disorders. In: Sadock BJ, Alcott SV, Ruiz P, editors. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 9^th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 1289-91.
2.	Zarghami M. Methamphetamine has changed the profile of patients utilizing psychiatric emergency services in Iran. Iran J Psychiatry Behav Sci 2011;5:1-5.
3.	United Nations Office for Drug Control and Crime Prevention (UNODCCP). Afghanistan Annual Opium Poppy Survey 2001. Vienna: The Office; 2001.
4.	Samii AW. Drug abuse: Iran's Iranrug Drug Office fBrown J World Aff 2003;9:283-99.
5.	The Wikipedia Organization. Wikipedia, the Free Encyclopedia 2011; [Methamphetamine]; 2011. Available from: http://www.fa.wikipedia.org. Persian. [Last accessed on 2015 Oct 23].
6.	Gitlow S. Substance Use Disorders. A Practical Guide. Philadelphia: Lippincott Williams and Wilkins; 2001.
7.	Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A, et al. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 2004;27:739-49.
8.	Weiss F, Koob GF. Drug addiction: Functional neurotoxicity of the brain reward systems. Neurotox Res 2001;3:145-56.
9.	Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann N Y Acad Sci 2001;937:1-26.
10.	Rose ME, Grant JE. Pharmacotherapy for methamphetamine dependence: A review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions. Ann Clin Psychiatry 2008;20:145-55.
11.	Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J. Pharmacotherapy of methamphetamine addiction: An update. Subst Abus 2008;29:31-49.
12.	Schuckit MA. The treatment of stimulant dependence. Addiction 1994;89:1559-63.
13.	Simon SL, Dacey J, Glynn S, Rawson R, Ling W. The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat 2004;27:59-66.
14.	Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: A literature review. Harv Rev Psychiatry 2005;13:141-54.
15.	Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 1997;25:192-216.
16.	Post RM, Weiss SR, Pert A. Cocaine-induced behavioral sensitization and kindling: Implications for the emergence of psychopathology and seizures. Ann N Y Acad Sci 1988;537:292-308.
17.	Robinson TE, Berridge KC. The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993;18:247-91.
18.	Agmo A, Medrano A, Garrido N, Alonso P. GABAergic drugs inhibit amphetamine-induced distractibility in the rat. Pharmacol Biochem Behav 1997;58:119-26.
19.	Dewey SL, Morgan AE, Ashby CR Jr, Horan B, Kushner SA, Logan J, et al. A novel strategy for the treatment of cocaine addiction. Synapse 1998;30:119-29.
20.	Gerasimov MR, Ashby CR Jr, Gardner EL, Mills MJ, Brodie JD, Dewey SL. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 1999;34:11-9.
21.	Morgan AE, Dewey SL. Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine. Synapse 1998;28:60-5.
22.	McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Valproate in psychiatric disorders: Literature review and clinical guidelines. J Clin Psychopharmacology 1989;12 Suppl 1:42-52s.
23.	Owens MJ, Nemeroff CB. Pharmacology of valproate. Psychopharmacol Bull 2003;37 Suppl 2:17-24.
24.	Post RM, Frye MA. Valproate. In: Sadock BJ, Alcott SV, Ruiz P, editors. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 9^th ed., Vol. 32. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 71-84.
25.	Li JX, Han R, Deng YP, Chen SQ, Liang JH. Different effects of valproate on methamphetamine- and cocaine-induced behavioral sensitization in mice. Behav Brain Res 2005;161:125-32.
26.	Strain EC, Anthony JC. Introduction and overview. In: Sadock BJ, Alcott SV, Ruiz P, editors. Kaplan and Sadock's Comprehensive Textbook of Psychiatry. 9^th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 1237-68.
27.	Obert JL, McCann MJ, Marinelli-Casey P, Weiner A, Minsky S, Brethen P, et al. The matrix model of outpatient stimulant abuse treatment: History and description. J Psychoactive Drugs 2000;32:157-64.
28.	Sussner BD, Smelson DA, Rodrigues S, Kline A, Losonczy M, Ziedonis D. The validity and reliability of a brief measure of cocaine craving. Drug Alcohol Depend 2006;83:233-7.
29.	Galloway GP, Newmeyer J, Knapp T, Stalcup SA, Smith D. A controlled trial of imipramine for the treatment of methamphetamine dependence. J Subst Abuse Treat 1996;13:493-7.
30.	Grabowski J, Shearer J, Merrill J, Negus S S. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive behaviors 2004; 29: 1439-1464.
31.	Piasecki MP, Steinagel GM, Thienhaus OJ, Kohlenberg BS. An exploratory study: The use of paroxetine for methamphetamine craving. J Psychoactive Drugs 2002;34:301-4.
32.	Shoptaw S, Huber A, Peck J, Yang X, Liu J, Dang J, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006;85:12-8.
33.	Kongsakon R, Papadopoulos KI, Saguansiritham R. Mirtazapine in amphetamine detoxification: A placebo-controlled pilot study. Int Clin Psychopharmacol 2005;20:253-6.
34.	Heinzerling KG, Shoptaw S, Peck JA, Yang X, Liu J, Roll J, et al. Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 2006;85:177-84.
35.	Wachtel SR, Ortengren A, de Wit H. The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend 2002;68:23-33.
36.	Johnson B, Rawson R, Elkashef A, Smith E, Campbell J, Haning W, et al. Ondansetron for the Treatment of Methamphetamine Dependence. In: The 66^th Annual Scientient of Methamphetamine De on Problems of Drug Dependence. San Juan, PR; 2004.
37.	Jayaram-Lindström N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 2008;33:1856-63.
38.	Jayaram-Lindström N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: A randomized, placebo-controlled trial. Am J Psychiatry 2008;165:1442-8.
39.	Newton TF, Roache JD, De La Garza R 2^nd, Fong T, Wallace CL, Li SH, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006;31:1537-44.
40.	Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008;33:1162-70.
41.	McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: A comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 2008;35:334-42.
42.	McElhiney MC, Rabkin JG, Rabkin R, Nunes EV. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV gay men: A pilot study. Am J Drug Alcohol Abuse 2009;35:34-7.
43.	Reid MS, Thakkar V. Valproate treatment and cocaine cue reactivity in cocaine dependent individuals. Drug Alcohol Depend 2009;102:144-50.

Advanced Biomedical Research